Bill 31 revises the Pharmacy Act to create a statutory definition of “unscheduled substance,” carve out regulatory control over how certain such substances may be sold outside pharmacies, and modernize prescription transmission rules. The text lets the government designate particular unscheduled substances as subject to sale conditions, and empowers regulators to require training or examinations for sellers and to delegate that authority to the Minister.
The bill also sets concrete technical and provenance requirements for electronic prescriptions (unique prescriber identifier, timestamp, and direct transmission through a secure, encrypted environment) and expressly bars dispensing on prescriptions sent by email. Finally, it updates a federal reference, removes a specific regulation provision, and replaces gendered language in the Act’s English text with gender-neutral wording.
These changes affect retail outlets, prescribers, pharmacists and the territorial regulator and shift day-to-day compliance and technology expectations across the N.W.T.
At a Glance
What It Does
Creates a legal category for 'unscheduled substances' tied to the National Drug Schedules; authorizes sale of such substances from non-pharmacy retail outlets subject to regulatory conditions; and prescribes technical, authentication and transmission requirements for electronic prescriptions. It also expands regulation-making powers to set training/exam and information obligations, and allows delegation of some training/exam authority to the Minister.
Who It Affects
Non-pharmacy retailers that may sell designated unscheduled substances, pharmacists who must accept or refuse faxed/electronic prescriptions based on new provenance rules, practitioners who generate e‑prescriptions, and the territorial regulator tasked with drafting and enforcing new regulations and training requirements.
Why It Matters
The bill shifts some access points for certain over‑the‑counter products out of the pharmacy-only sphere while simultaneously imposing new compliance, information and technical requirements to protect safe use. For compliance officers and pharmacy operators this creates new operational pathways and regulatory obligations; for prescribers it creates minimum standards for electronic transmission infrastructure.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act defines “unscheduled substance” in two ways: items listed in the unscheduled category of the National Drug Schedules and any substance that a regulation removes from a federal drug schedule without moving it into another schedule. That framing ties territorial control to a national classification but leaves the territorial regulations as the mechanism to flag particular unscheduled substances as subject to sale conditions within the N.W.T.
When the regulator designates an unscheduled substance as one that may be sold only under prescribed conditions, the seller — whether a pharmacy or a non‑pharmacy retailer — must ensure recipients have “adequate information” about appropriate use and must comply with any additional conditions the regulations impose. The Act explicitly authorizes regulations to set training or examination requirements for classes of sellers and to delegate the imposition of those requirements to the Minister, creating a two‑step rulemaking and administrative compliance structure.On prescriptions and dispensing, the Act replaces permissive language and tightens provenance controls.
Faxed prescriptions will only support dispensing if the fax is sent directly from the practitioner or from staff at the practitioner’s place of practice. Electronic prescriptions must be generated by the practitioner, carry the practitioner’s unique identifier affixed at issuance, record the date/time of transmission, and be transmitted directly in a secure, encrypted environment; prescriptions sent by ordinary email are explicitly excluded.
The pharmacist’s duty is tightened — they must be satisfied of authenticity, validity and integrity before dispensing.The bill also updates cross‑references to federal scheduling, removes a specified section from the existing Pharmacy Regulations, and performs broad housekeeping by replacing gender‑specific terms with gender‑neutral language. Practically, that means the regulatory framework will now do the heavy lifting: the Act sets enabling standards and technical requirements while leaving substance‑level restrictions, retail conditions and training modalities to regulation-making and Ministerial direction.
The Five Things You Need to Know
The Act requires an electronic prescription to carry the prescribing practitioner’s unique identifier affixed at issuance and to include the date and time it was transmitted to the pharmacist.
A pharmacist may only dispense on an electronic prescription if it is transmitted directly from a practitioner through a secure, encrypted environment; prescriptions sent by email are expressly excluded.
The Act allows non‑pharmacy retail establishments to sell unscheduled substances, but the regulator may designate particular unscheduled substances as “prescribed” and impose information, training or other conditions on sellers.
Regulations may impose training or examination requirements for sellers of certain unscheduled substances and the Act authorizes delegating that power to the Minister for implementation.
The Pharmacy Regulations are amended by repealing section 6.1 (the bill removes that specific regulatory provision without replacing it in the text).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Defines 'unscheduled substance' and updates 'practice of pharmacy'
The Act inserts a two‑part definition of “unscheduled substance”: substances in the National Drug Schedules’ unscheduled category and substances removed from a federal schedule by regulation without placement in another schedule. It also modifies the statutory description of the 'practice of pharmacy' to explicitly include sale and provision of information about unscheduled substances. That anchors future regulatory control to a national categorization while making the regulator responsible for territorial application.
Permits retail sale outside pharmacies, subject to regulation
New section 18.1 allows sale of unscheduled substances from establishments other than pharmacies, but creates a two‑tier structure: generic unscheduled substances may be sold broadly, while the regulator can single out 'prescribed unscheduled substances' and attach conditions. Those conditions include mandatory information for recipients and any other regulatory constraints — the actual list of which will come from subordinate regulations rather than the statute itself.
Tightens provenance rules for faxed and electronic prescriptions
The bill replaces permissive language with mandatory prohibitions and spells out provenance requirements. For faxed prescriptions a pharmacist may only dispense if the fax was sent directly from the practitioner or the practitioner’s staff. For electronic prescriptions the statute requires practitioner creation, an affixed unique prescriber identifier, a timestamp of transmission, and direct transmission through a secure, encrypted platform. The law also clarifies that ordinary email transmission does not qualify as an acceptable electronic prescription.
Clarifies pharmacist obligations and limited prescribing for continuity of care
The text modernizes language about a pharmacist’s duty to be satisfied regarding a prescription’s validity, integrity and authenticity. It also preserves and slightly reframes the pharmacist’s ability to supply a limited quantity of a drug for continued care, explicitly allowing drugs listed under the federal Prescription Drug List to be included; regulatory limits and conditions on that dispensing are left in place.
New regulation‑making heads of power for unscheduled substances, and Ministerial delegation
Legislative authority is added to permit regulations that set requirements, restrictions or conditions on the retail sale, supply and distribution of particular unscheduled substances or classes. The Act specifically lists training/examination requirements and information obligations and authorizes delegating to the Minister the power to impose training/exam requirements — a structural choice that accelerates administrative implementation but centralizes discretion.
Housekeeping: gender neutrality and cross‑reference updates
The Act makes extensive English‑language edits substituting gender‑neutral pronouns and fixes an outdated federal schedule reference. These are technical changes intended to modernize and correct the statute. Separately, the bill repeals section 6.1 of the existing Pharmacy Regulations; because the text does not replace that regulatory provision, the practical effect will depend on what that deleted provision formerly governed.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers in remote and underserved communities — they may gain more local access to certain over‑the‑counter products when non‑pharmacy retailers are authorized to sell designated unscheduled substances, reducing travel and wait times for basic items.
- Non‑pharmacy retailers — eligible retail outlets get a new product category to stock and sell, potentially expanding revenue streams if they meet regulatory conditions.
- Pharmacists — clearer technical standards for accepting electronic prescriptions reduce uncertainty around provenance and place the onus for secure transmission on prescribers and their systems.
- Territorial government — gains flexible regulatory tools (including delegation to the Minister) to respond quickly to public‑health or market developments without statute amendments.
Who Bears the Cost
- Non‑pharmacy retailers and their staff — they will incur compliance costs to provide required information, complete training or examinations (if imposed), and adapt point‑of‑sale practices to regulatory conditions.
- Prescribers and small clinics — must use systems capable of producing prescriptions with unique identifiers, timestamps and secure direct transmissions; practitioners without electronic infrastructure may need upgrades.
- Pharmacy regulator and enforcement bodies — expanded regulatory scope and delegation increase rule‑making, oversight and enforcement responsibilities, potentially requiring new inspections and complaint handling resources.
- Pharmacies — although permitted to continue dispensing, pharmacists must verify stricter provenance and authenticity elements for e‑prescriptions, which may slow workflows and necessitate new verification processes or software.
Key Issues
The Core Tension
The bill aims to widen access by allowing certain products to be sold outside pharmacies while simultaneously tightening professional and technical controls (training requirements, information duties, encrypted e‑prescription standards). That creates an inherent trade‑off between access and centralized oversight: improving convenience and market entry risks fragmenting safeguards unless regulators craft clear, enforceable conditions — a balance with no one‑size‑fits‑all solution.
The Act delegates substantial detail to the regulations: which unscheduled substances will attract sale conditions, what constitutes 'adequate information' for recipients, the content and scope of any required training or examinations, and how delegated Ministerial powers will be exercised. That design gives administrators flexibility but creates implementation risk: uneven or delayed regulatory drafting could leave stakeholders uncertain about compliance expectations for months.
The delegated authority to impose training or examinations is particularly consequential — it allows the executive to set competence requirements without primary‑legislation debate, which speeds response but concentrates discretion.
Technical prescription requirements improve provenance but raise practical issues in the N.W.T.’s dispersed health system. Requiring direct, secure, encrypted transmission and a unique prescriber identifier presumes prescribers and rural clinics have interoperable, certified e‑prescribing platforms; smaller practices may face upgrade costs or transitional gaps.
The explicit ban on email transmission aims to prevent easy forgery or tampering, but it may produce edge cases (forwarded secure messages, hybrid fax‑email workflows) that require interpretive guidance from the regulator. Finally, repealing a specific regulatory provision (Pharmacy Regulations section 6.1) without replacement changes the regulatory baseline in ways that are not transparent in the bill text — stakeholders need the forthcoming regulations to understand the net effect.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.